Despite its failure in human clinical trials, the observed benefits of RSG in preclinical models of AD, together with the abundance of data supporting the role of impaired brain insulin signaling in AD pathology, suggest anti-diabetic drugs should be further investigated as a therapeutic option for AD. The gene discussed is INS; the disease is Alzheimer disease.